Patent intelligence · US
US 11078298
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
Patent details — US 11078298
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 3, 2021
- Expiration
- Jul 29, 2041
- Applicant
- BANYAN BIOMARKERS, INC.
- Claims
- 2
- CPC classes
- A61P, A61P17/02, A61P21/04, A61P25/00
Quick answer
US 11078298 (Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods) is held by BANYAN BIOMARKERS, INC.. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BANYAN BIOMARKERS, INC.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P17/02, A61P21/04, A61P25/00, A61P25/16, A61P25/28
More from BANYAN BIOMARKERS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12077601
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11885817
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11692030
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11598782
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11447500
Thienopyridine derivatives and pharmaceutical composition comprising same
granted -
US 11186873
Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
granted -
US 11008622
Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof
granted
Frequently asked questions
What is US patent 11078298?
US 11078298 (Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods) is held by BANYAN BIOMARKERS, INC.. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11078298?
BANYAN BIOMARKERS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 11078298 expire?
Our index shows an expiration date of Jul 29, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.